Patient characteristics
| Variable . | Entire cohort (N = 802) . | MAC (n =321; 40%) . | RIC (n = 481; 60%) . | P . |
|---|---|---|---|---|
| Age at HCT, median, y | 59.58 (range, 18.58-78.64; IQR, 52.49-65.05) | 54.29 (range, 18.58-74.51; IQR, 45.48-61.14) | 61.98 (range, 19.96-78.64; IQR, 56.72-66.43) | <.0001 |
| Time to HCT, median, mo | 4.47 (range, 0.23-137.73; IQR, 3.09-6.69) | 4.37 (range, 0.26-108.83; IQR, 2.79-6.7) | 4.6 (range, 0.23-137.73; IQR, 3.19-6.67) | .2669 |
| Engraftment | 741 (95.2) | 297 (94.6) | 444 (95.7) | .5906 |
| Time to engraftment, median, d | 17 (range, 3-89; IQR, 14-20) | 17 (range, 3-89; IQR, 13.5-20) | 17 (range, 4-77; IQR, 14-20) | .8290 |
| Source of stem cells (peripheral blood) | 722 (90.1) | 274 (85.4) | 448 (93.3) | .0003 |
| Disease status | .1045 | |||
| Advanced | 364 (45.4) | 152 (47.4) | 212 (44.1) | |
| CR1 | 396 (49.4) | 147 (45.8) | 249 (51.8) | |
| CR1 | 42 (5.2) | 22 (6.9) | 20 (4.2) | |
| KPS* | .1088 | |||
| Poor (<80%) | 66 (9) | 20 (6.7) | 46 (10.5) | |
| Good (≥80%) | 671 (91) | 277 (93.3) | 394 (89.5) | |
| Donor HLA | .1358 | |||
| MSD | 340 (42.4) | 141 (43.9) | 199 (41.4) | |
| URD 10/10 | 370 (46.1) | 152 (47.4) | 218 (45.3) | |
| URD 9/10 | 92 (11.5) | 28 (8.7) | 64 (13.3) | |
| Donor to patient sex | .0251 | |||
| Female to male | 166 (20.9) | 53 (16.8) | 113 (23.6) | |
| Other | 628 (79.1) | 263 (83.2) | 365 (76.4) | |
| Cytogenetic risk | .0339 | |||
| Intermediate | 538 (67.1) | 201 (62.6) | 337 (70.1) | |
| Poor | 264 (32.9) | 120 (37.4) | 144 (29.9) | |
| T-cell depletion | <.0001 | |||
| No TCD | 263 (32.8) | 138 (43) | 125 (26) | |
| ATG/Campath | 539 (67.2) | 183 (57) | 356 (74) | |
| Use of TBI | .0008 | |||
| Yes | 624 (77.8) | 230 (71.7) | 394 (81.9) | |
| No | 178 (22.2) | 91 (28.3) | 87 (18.1) | |
| CMV status (patient) | .2589 | |||
| Negative | 248 (31.9) | 90 (29.4) | 158 (33.5) | |
| Positive | 529 (68.1) | 216 (70.6) | 313 (66.5) | |
| CMV status (donor) | .9626 | |||
| Negative | 383 (49.3) | 151 (49) | 232 (49.5) | |
| Positive | 394 (50.7) | 157 (51) | 237 (50.5) |
| Variable . | Entire cohort (N = 802) . | MAC (n =321; 40%) . | RIC (n = 481; 60%) . | P . |
|---|---|---|---|---|
| Age at HCT, median, y | 59.58 (range, 18.58-78.64; IQR, 52.49-65.05) | 54.29 (range, 18.58-74.51; IQR, 45.48-61.14) | 61.98 (range, 19.96-78.64; IQR, 56.72-66.43) | <.0001 |
| Time to HCT, median, mo | 4.47 (range, 0.23-137.73; IQR, 3.09-6.69) | 4.37 (range, 0.26-108.83; IQR, 2.79-6.7) | 4.6 (range, 0.23-137.73; IQR, 3.19-6.67) | .2669 |
| Engraftment | 741 (95.2) | 297 (94.6) | 444 (95.7) | .5906 |
| Time to engraftment, median, d | 17 (range, 3-89; IQR, 14-20) | 17 (range, 3-89; IQR, 13.5-20) | 17 (range, 4-77; IQR, 14-20) | .8290 |
| Source of stem cells (peripheral blood) | 722 (90.1) | 274 (85.4) | 448 (93.3) | .0003 |
| Disease status | .1045 | |||
| Advanced | 364 (45.4) | 152 (47.4) | 212 (44.1) | |
| CR1 | 396 (49.4) | 147 (45.8) | 249 (51.8) | |
| CR1 | 42 (5.2) | 22 (6.9) | 20 (4.2) | |
| KPS* | .1088 | |||
| Poor (<80%) | 66 (9) | 20 (6.7) | 46 (10.5) | |
| Good (≥80%) | 671 (91) | 277 (93.3) | 394 (89.5) | |
| Donor HLA | .1358 | |||
| MSD | 340 (42.4) | 141 (43.9) | 199 (41.4) | |
| URD 10/10 | 370 (46.1) | 152 (47.4) | 218 (45.3) | |
| URD 9/10 | 92 (11.5) | 28 (8.7) | 64 (13.3) | |
| Donor to patient sex | .0251 | |||
| Female to male | 166 (20.9) | 53 (16.8) | 113 (23.6) | |
| Other | 628 (79.1) | 263 (83.2) | 365 (76.4) | |
| Cytogenetic risk | .0339 | |||
| Intermediate | 538 (67.1) | 201 (62.6) | 337 (70.1) | |
| Poor | 264 (32.9) | 120 (37.4) | 144 (29.9) | |
| T-cell depletion | <.0001 | |||
| No TCD | 263 (32.8) | 138 (43) | 125 (26) | |
| ATG/Campath | 539 (67.2) | 183 (57) | 356 (74) | |
| Use of TBI | .0008 | |||
| Yes | 624 (77.8) | 230 (71.7) | 394 (81.9) | |
| No | 178 (22.2) | 91 (28.3) | 87 (18.1) | |
| CMV status (patient) | .2589 | |||
| Negative | 248 (31.9) | 90 (29.4) | 158 (33.5) | |
| Positive | 529 (68.1) | 216 (70.6) | 313 (66.5) | |
| CMV status (donor) | .9626 | |||
| Negative | 383 (49.3) | 151 (49) | 232 (49.5) | |
| Positive | 394 (50.7) | 157 (51) | 237 (50.5) |
Values are n (%) unless otherwise noted.
ATG, antithymocyte globulin; CMV, cytomegalovirus; CR, complete remission; KPS, Karnofsky Performance Status; TBI, total body irradiation.
Data missing on 65 patients in registry.